And then there’s naturally the staff associated and otherwise. I can’t estimate what that is. That is different for each imaging center and hospital. But overall, PET/CT has been adopted in this marketplace for decades. It continues to grow. And I think we’ve seen the benefits of PYLARIFY cause a number of institutions to even think about increasing number of PET/CT scanners that they have to be able to better support the patients they serve and the referring physicians that come to them. I don’t know if that helps answer the question.
Mary Anne Heino: I would just add, one, that the whole market that was built by FDG is really what built the PET scanning market, especially in oncology, in the United States market. So it’s well built out, and I think it’s well — the financial aspects of it are well understood, but they are also then different by each product. Because, as Paul noted, while the medical art associated with offering a PET scan may be similar across different products, it would be the cost of the tracer that would be different.
Operator: Thank you. And for your next question, it comes from the line of David Turkaly from JMP Securities. David, your line is open. Please ask your question.
David Turkaly: Great. Good morning. Maybe just a real quick one for Bob. Thanks for pointing out some of the impacts in the quarter. But if we looked at the seasonal trends, the holiday and then the one less selling day. Is there any way you could put like an approximate dollar amount on what you think that cost you in the quarter?
Bob Marshall: The way I’ll answer that, David, is maybe by sort of normalizing or adjusting to the sequential growth rate. So, if you make the adjustments, and we do see this, and we pointed out coming out of the last quarter that, we would see increasing sort of impacts from holidays, particularly going to July 4 in this case and Labor Day. And then, we will see it again when we get to Thanksgiving and then the week between Christmas and New Year’s. But if we look at the impact of the things that we highlighted, we would have expected that the adjusted growth rate sequentially to be something in the mid-single digits, which is why we kind of use the language around a consistent quarterly sequential growth rate. Because if you look at the growth rate from Q1 to Q2 and now Q2 to Q3, and then the implied guidance, if you will, in Q4, they’re all very similar kinds of growth rates.
Paul Blanchfield: David, maybe I’ll just add. I think when we look at the dynamics of the quarter, and as I highlighted on the prepared remarks, June, July and August had relatively consistent volumes on a weekly basis, taking out the holiday weeks, if you will. But where we saw growth continue at more historical levels was the August to September and the September to October. And we believe that’s consistent with what we see across the industry. Indeed, DEFINITY, which we’ve been at for 22-plus years, our third quarter is always our weakest quarter and is even down sequentially. And where you look at other procedural-based reporting organizations, July and August are relatively slow. Now in the past couple of years, we may not have been able to see that and our financials, may not have depicted that as much because the growth trajectory of PYLARIFY at 100%-plus growth, activating new PMS, adding new accounts, that doesn’t necessarily stick out.
But if you look at last year as an example, our sequential growth Q2 to Q3 was also the lowest sequential growth of the year. And so that’s consistent with what Bob just highlighted.
Operator: Thank you. And we have a follow-up question from Roanna Ruiz from Leerink. Please go ahead.
Roanna Ruiz: Just a quick one for me. I’m not sure if I heard it on the call. But have you mentioned the current market share for PYLARIFY in the quarter relative to last quarter? I think last quarter it was around 70% penetrated.
